Tenon Medical, Inc.

Greetings and welcome to the Tenon Medical Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Your host today, Steve Foster, Chief Executive Officer, and President Steve Van Dyck, Chief Financial Officer, will present results of operations for the second quarter ended June 30th, 2022, and provide a corporate update. A press release detailing these results was released today and is available on the investor relations section of our company's website, www.tenonmed.com. Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. We should also review our most recent prospectus and form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading risk factors. At this time, I'll turn the call over to Tenon's Chief Executive Officer, Steve Foster.

Thank you, Mike. I appreciate you and good afternoon to everyone. I'm pleased to welcome you to today's second quarter 2022 financial results and corporate update conference call for Tenon Medical. 2022 was a milestone year for our organization, transitioning to a public company and positioning us for commercialization of our catamaran SI joint fusion system. In the second quarter, we closed on a $16 million IPO, providing the necessary funds to execute on our commercial plans and support our mission to deliver a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. For those of you I've not had the opportunity to meet, I'd like to briefly describe our opportunities. The sacroiliac joint, or SI joint, is the last segment of the spine, connecting the sacrum to the ilium. The literature estimates that approximately 25% of all lower back pain may be attributed to dysfunction of the SI joint, often presenting as sciatica-like symptoms, producing buttock and upper leg pain. The most common causes of SI joint pain are injuries, pregnancy and childbirth, and degeneration. Managing SI joint symptoms typically involves physical therapy, stretching exercises, pain medications, and joint injections. While many patients respond to non-surgical treatment, surgical options to fuse the joint and stop painful motion may be recommended. Catamaran SI joint fusion system is intended to facilitate SI joint fusion to treat SI conditions, including sacroiliac joint disruptions, and degenerative sacroiliitis. The global SI joint market is a major untapped market opportunity, estimated to grow to 650-plus million by 2028 at a compounded annual growth rate of 18%. This growth is being driven by improved surgical approaches, specialized implant designs, procedure safety and efficacy, clear physician reimbursement, and growing recognition from physicians seeking better options for their patients. We founded Tenon Medical, Inc. in 2012 and developed a proprietary U.S. Food and Drug Administration cleared surgical implant system, which we call the Catamaran SI Joint Fusion System. The system offers a novel, less invasive, inferior posterior approach to the SI joint using a single, robust titanium implant. This implant is the catamaran fixation device, which transfixes the SI joint ileum to sacrum. Specialized instrumentation is utilized to harvest the patient's own bone during the drilling process and properly place the fixation device. The procedure provides for disruption, fixation, and grafting of the joint to help facilitate the fusion response. And these are required aspects of any authentic arthrodesis. We believe that the implant design and procedure we have developed along with 2D and 3D imaging protocols for proper implantation will continue to be well received by the clinician community who have been looking for a next generation device. Our initial clinical results indicate that the catamaran system implant is promoting fusion across the joint as evidenced by post-op CT scans which are a gold standard for fusion assessment in the surgical community. The Catamaran system has been designed to produce broad and demonstrable advantages over market competitors. Additionally, and equally important, is the surge in response to the benefits of the system, which have been extremely positive to date. Chanon and its commercial partner have been focusing on compelling physicians to workshop settings and then assisting them with access to do cases in their facility. We are preparing for a full national launch of the technology at the upcoming North American Spine Society meeting to be held in Chicago in October this fall. We continue to target physicians who have been trained on SI procedures or have significant experience with SI surgical technologies. To date, we have hosted 21 physician education workshops. In addition, Tenana has completed design of a synthetic trainer model that will deliver an accelerated ability to train locally and to do so in a very cost-effective manner. Lastly, Tenon Medical is preparing to initiate a prospective multi-center post-market study of the catamaran SI joint fusion system. The objective of this post-market study is to report on the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroilitis treated with the catamaran system. The study is designed to enroll up to 50 patients at up to 10 clinical sites in the United States. The company is currently in the process of identifying and qualifying clinical sites with plans to initiate enrollment in the fall of 2022. We continue to be encouraged by our progress towards bringing our catamaran system to market and the increasing number of surgical procedures utilizing the system. Early results show the system delivering on its promises in providing our physician customers with an enhanced option to treat their patients suffering from debilitating SI joint issues. With that, I'll now turn it over to Mr. Steve Van Dyck, our Chief Financial Officer, to discuss our financials.

Thank you, Steve. I will give a succinct review of our financial results. A full breakdown is available in our regulatory filings and in a press release that crossed the wire this afternoon. Revenue was $135,000 in the second quarter into June 30, 2022, an increase of 514% compared to the $22,000 in the comparable year-ago period. The increase was primarily due to a 433% increase in the number of surgical procedures in which the catamaran system was used. Revenue for the six months ended June 30th, 2022 was $206,000, up 457% from the $37,000 in the year-ago period. Gross loss in the three months ended June 30th, 2022 was $136,000 compared to a gross profit of $13,000 in the comparable year-ago quarter, primarily due to the increase in operations overhead and spending. gross margin percentage decreased from 59% to a negative 101%, primarily driven by higher operations overhead spending and partially offset by higher revenue per procedure, which resulted from an amended and restated national distribution agreement. Operating losses totaled 5.5 million for the second quarter of 2022, compared to a loss of 1.6 million in the second quarter of 2021. The increase in operating expenses was a result of the creation of an infrastructure to support future growth and the ongoing transition to a public operating company. The operating loss for the second quarter of 2022 includes a $1.5 million charge for the issuance of common stock under an anti-dilution provision of an agreement, a $574,000 charge for the settlement of our arbitration with our CEO, prior CEO, as well as an increase in stock-based compensation of $491,000 over the second quarter of 2021. Net loss was $5.5 million for the second quarter of 2022 compared to a loss of $1.7 million in the same period of 2021. Net loss for the six months ended June 30, 2022, was $7.8 million compared to $1.9 million in a prior year period. we do expect to incur additional losses in the future. As of June 30, 2022, cash, cash equivalents, and investments totaled $16 million. The company believes that the cash, cash equivalents, and investments will enable Tenon Medical to fund the hiring of additional personnel, product development, and sales and marketing activities, which include clinician training and clinical research. I'll now turn the call back to Steve Foster for closing thoughts.